Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 - Episode 13

Perspectives of IMerge Study

August 10, 2024

Guillermo Garcia-Manero, MD, Rami Komrokji, MD, Esther Natalie Oliva, MD , Amer Zeidan, MBBS, MHS, Thomas Cluzeau, MD, PhD

Medical professionals deliberate on patient selection criteria for second-line imetelstat treatment in lower-risk myelodysplastic syndromes, incorporating findings from the IMerge study into their considerations.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification

EP. 2: Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS 

EP. 3: Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies

EP. 4: Review of the COMMANDS Trial

EP. 5: Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial

EP. 6: Clinical Implications of COMMANDS Trial in Clinical Practice

EP. 7: Treatment Decision-Making Based on the COMMANDS Trials

EP. 8: Exploring Biomarker Analysis, Real-World Data, and Quality of Life in LR-MDS: Insights from EHA 2024

EP. 9: Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data

EP. 10: Safety Profile of Available Frontline Treatments LR-MDS

EP. 11: 1L treatment of lower-risk MDS beyond luspatercept

EP. 12: Sequencing Second-Line Treatments for LR-MDS

Now Viewing

EP. 13: Perspectives of IMerge Study

EP. 14: Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024

EP. 15: EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates

EP. 16: Final Thoughts on EHA 2024 Data for Lower-Risk MDS

Please comment on which patients you would consider 2L imetelstat for patients with LR-MDS.
1. Please provide a summary of the IMerge study, evaluating imetelstat in patients that R/R to ESAs in LR-MDS. (Platzbecker U, Santini V, Fenaux P, et al. Lancet. 2024;403(10423):249-260.)
2. Dr Komrokji: How does the latest follow up from the IMergestudy support the use of imetelstat in patients with LR-MDS?